Kalaris Therapeutics, Inc. (NasdaqGM: KLRS)
Health Care · Biotechnology · US
$4.15
+1.72% today · +63.2% 1Y
Kalaris Therapeutics, Inc. (NasdaqGM: KLRS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $97.12M and employs 20 people.
Over the last twelve months the share price has gained 63.2%, trading between 2.14 and 11.88.
Tweenvest scores Kalaris Therapeutics, Inc. across four factors: quality 31/100. Its strongest factor is quality.
KLRS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $97.12M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.18
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $11.88
- 52-week low
- $2.14
- Avg volume (3M)
- —
- Shares outstanding
- 23.80M
- Employees
- 20
- Next earnings
- —
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
- Founded
- 2019
- Listed since
- Jul 30, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.